Gilead Sciences, Inc. vs Lantheus Holdings, Inc.: Annual Revenue Growth Compared

Biotech Giants' Revenue: A Decade of Divergence

__timestamp	Gilead Sciences, Inc.	Lantheus Holdings, Inc.
Wednesday, January 1, 2014	24890000000	301600000
Thursday, January 1, 2015	32639000000	293461000
Friday, January 1, 2016	30390000000	301853000
Sunday, January 1, 2017	26107000000	331378000
Monday, January 1, 2018	22127000000	343374000
Tuesday, January 1, 2019	22449000000	347337000
Wednesday, January 1, 2020	24689000000	339410000
Friday, January 1, 2021	27305000000	425208000
Saturday, January 1, 2022	27281000000	935061000
Sunday, January 1, 2023	27116000000	1296429000
Monday, January 1, 2024	28754000000

Infusing magic into the data realm

A Tale of Two Biotech Giants: Revenue Growth from 2014 to 2023

In the dynamic world of biotechnology, Gilead Sciences, Inc. and Lantheus Holdings, Inc. have charted distinct paths over the past decade. From 2014 to 2023, Gilead Sciences, a leader in antiviral drugs, saw its revenue peak in 2015, with a subsequent decline and stabilization around $27 billion annually. This represents a 17% drop from its 2015 high, reflecting market challenges and evolving product lines.

Conversely, Lantheus Holdings, known for its diagnostic imaging agents, has experienced a remarkable revenue surge. Starting at a modest $300 million in 2014, Lantheus's revenue skyrocketed by over 330% to approximately $1.3 billion by 2023. This growth underscores its strategic expansions and successful product innovations.

These contrasting trajectories highlight the diverse strategies and market dynamics within the biotech sector, offering valuable insights for investors and industry enthusiasts alike.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025